GAO Memory Supplement Review Recalls FDA's Regulatory Challenges
This article was originally published in The Rose Sheet
GAO recommends better cooperation between FDA and FTC and more public outreach are key to preventing consumers from believing noncompliant cognitive benefit claims for supplements.
You may also be interested in...
Yohimbe Ban Suggested, 'God' Warned: Health And Wellness Industry News
ED-spiked supplement importers identified; FDA and FTC act on GAO outreach suggestion; ephedra-like rulemaking needed for yohimbe – study; and God's book among violative claims by Florida firm.
Industry Eyes NDI Notification Common Ground With Gottlieb-Led FDA
CHPA and CRN look forward to working with FDA to develop a path for the identification of pre-DSHEA ingredients, but say the FDA’s revised draft guidance for new dietary ingredient notifications still hampers innovation.
FTC Enforcement Hangs Over Memory Product Firm After Overlooking NAD Review
KNH Online did not respond to NAD's request for information supporting claims for its Adderin supplement, including the statement "clinically proven to sky-rocket concentration by 312%" and a customer testimonial that "it started working within minutes of taking it … I experienced a mental clarity that I’d never felt before."